COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study (RITE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02947945
Recruitment Status : Unknown
Verified September 2017 by Michael Wechsler, National Jewish Health.
Recruitment status was:  Recruiting
First Posted : October 28, 2016
Last Update Posted : September 14, 2017
Teva Pharmaceuticals USA
Information provided by (Responsible Party):
Michael Wechsler, National Jewish Health

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018